Results 11 to 20 of about 22,239 (295)

The purification and characterisation of novel dipeptidyl peptidase IV-like activity from bovine serum [PDF]

, 2004
The discovery of a potentially novel proline-specific peptidase from bovine serum is presented which is capable of cleaving the dipeptidyl peptidase IV (DPIV) substrate Gly-Pro-MCA.
Abbott, Birney, Cunningham, De Meester, De Meester, Duke-Cohan, Duke-Cohan, Duke-Cohan, Durinx, Gilmartin, Hegen, Hopsu-Havu, Huang, Iwaki-Egawa, Kin, Laemmli, Malik, Mentlein, Mentlein, Ohkubo, Ohnishi, Pineiro-Sanchez, Scanlan, Schon, Sedo, Sedo, Shibuya-Saruta, Smith, Stockel-Maschek, Underwood, Yaron, Yoshimoto   +31 more
core   +1 more source

Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice

Journal of Pharmacological Sciences, 2007
E3024 (3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate) is a dipeptidyl peptidase IV (DPP-IV) inhibitor. Since the target of both DPP-IV inhibitors and α-glucosidase inhibitors is the lowering of postprandial ...
Kazuto Yamazaki, Takashi Inoue, Nobuyuki Yasuda, Yoshiaki Sato, Tadashi Nagakura, Osamu Takenaka, Richard Clark, Takao Saeki, Isao Tanaka   +8 more
doaj   +1 more source

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2021
The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM).
Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K. Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Esong Kim, Sei Hyun Baik   +8 more
doaj   +1 more source

What doesn't kill you makes you stranger: Dipeptidyl peptidase-4 (CD26) proteolysis differentially modulates the activity of many peptide hormones and cytokines generating novel cryptic bioactive ligands [PDF]

, 2019
Dipeptidyl peptidase 4 (DPP4) is an exopeptidase found either on cell surfaces where it is highly regulated in terms of its expression and surface availability (CD26) or in a free/circulating soluble constitutively available and intrinsically active form.
Aguilar-Pérez, Alexandra, Awad, Mohamed E., Eisa, Nada H., Elmansi, Ahmed M., Fulzele, Sadanand, Hamrick, Mark W., Herberg, Samuel, Hill, William D., Hussein, Khaled A., Isales, Carlos M., Kondrikov, Dmitry, McGee-Lawrence, Meghan E., Periyasamy-Thandavan, Sudharsan, Volkman, Brian F.   +13 more
core   +1 more source

Vildagliptin induced cutaneous leukocytoclastic vasculitis: A case report

Medicine Science, 2018
Vildagliptin is a new generation theurapeutic agent of diabetes mellitus which belongs to dipeptidyl peptidase-IV inhibitor class acting via the incretin hormone system.
Serhat Sayin, Ethem Omeroglu, Semra Aslan Bilgin   +2 more
doaj   +1 more source

Risk of Pancreatic Cancer and Use of Dipeptidyl Peptidase 4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matching Analysis [PDF]

Endocrinology and Metabolism, 2023
Background The effects of dipeptidyl peptidase 4 (DPP-4) inhibitors over the course of long-term treatment remain unclear, and concerns have been raised regarding the role of DPP-4 inhibitors in carcinogenesis in the pancreas.
Mee Kyoung Kim, Kyungdo Han, Hyuk-Sang Kwon, Soon Jib Yoo   +3 more
doaj   +1 more source

The cardiovascular safety of incretin-based therapies: a review of the evidence [PDF]

, 2013
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality in people with diabetes and therefore managing cardiovascular (CV) risk is a critical component of diabetes care. As incretin-based therapies are effective recent additions to the
Petrie, J.R.
core   +2 more sources

Solvent and thermal stability, and pH kinetics, of proline-specific dipeptidyl peptidase IV-like enzyme from bovine serum [PDF]

, 2007
Proline-specific dipeptidyl peptidase-like (DPP IV; EC 3.4.14.5) activity in bovine serum has attracted little attention despite its ready availability and the paucity of useful proline-cleaving enzymes.
Abbott, Barry, Brendan F. O’Connor, Buckley, Bušek, Chruscinska, Ciarán Ó’Fágáin, De Meester, Deborah M. Ruth, Demuth, Dixon, Duke-Cohan, Dunn, Durinx, Edens, Engel, Fersht, FitzGerald, Gonzalez, Gorren, Grasso, Jagath, Khmelnitsky, Kikkawa, Lambeir, Lee, Maes, Mentlein, Mittal, Ogino, Ohkubo, Ohnishi, O’Cuinn, Poltorak, Poltorak, Rasmussen, Sears, Sentandreu, Sheehan, Smith, Séamus J. Buckley, Trubetskoy, Yaron, Yoshimoto   +43 more
core   +1 more source

Efficacy and safety of teneligliptin added to metformin in Chinese patients with type 2 diabetes mellitus inadequately controlled with metformin: A phase 3, randomized, double‐blind, placebo‐controlled study

Endocrinology, Diabetes & Metabolism, 2021
Introduction We evaluated the efficacy and safety of teneligliptin compared with placebo when added to metformin therapy in Chinese patients with type 2 diabetes inadequately controlled with metformin monotherapy.
Linong Ji, Ling Li, Jianhua Ma, Xuefeng Li, Dongmei Li, Bangzhu Meng, Weiping Lu, Jiao Sun, Yanmei Liu, Gen Takayanagi, Yi Wang   +10 more
doaj   +1 more source

Characterization of combined linagliptin and Y2R agonist treatment in diet-induced obese mice

Scientific Reports, 2021
Dipeptidyl peptidase IV (DPP-IV) inhibitors improve glycemic control by prolonging the action of glucagon-like peptide-1 (GLP-1). In contrast to GLP-1 analogues, DPP-IV inhibitors are weight-neutral.
Henrik H. Hansen, Rikke V. Grønlund, Tamara Baader-Pagler, Peter Haebel, Harald Tammen, Leif Kongskov Larsen, Jacob Jelsing, Niels Vrang, Thomas Klein   +8 more
doaj   +1 more source